119 related articles for article (PubMed ID: 10646483)
1. Future trends in the treatment of rheumatoid arthritis: cytokine targets.
Breedveld FC
Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():11-3. PubMed ID: 10646483
[TBL] [Abstract][Full Text] [Related]
2. The mode of action of cytokine inhibitors.
Arend WP
J Rheumatol Suppl; 2002 Sep; 65():16-21. PubMed ID: 12236617
[TBL] [Abstract][Full Text] [Related]
3. The role of cytokines in osteoarthritis pathophysiology.
Fernandes JC; Martel-Pelletier J; Pelletier JP
Biorheology; 2002; 39(1-2):237-46. PubMed ID: 12082286
[TBL] [Abstract][Full Text] [Related]
4. Cytokine network and its manipulation in rheumatoid arthritis.
Malaviya AM
J Assoc Physicians India; 2006 Jun; 54 Suppl():15-8. PubMed ID: 16909710
[TBL] [Abstract][Full Text] [Related]
5. Emerging cytokine targets in rheumatoid arthritis.
Asquith DL; McInnes IB
Curr Opin Rheumatol; 2007 May; 19(3):246-51. PubMed ID: 17414950
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of antigen-presenting cell function and stimulation of human peripheral blood mononuclear cells to express an antiinflammatory cytokine profile by the stress protein BiP: relevance to the treatment of inflammatory arthritis.
Corrigall VM; Bodman-Smith MD; Brunst M; Cornell H; Panayi GS
Arthritis Rheum; 2004 Apr; 50(4):1164-71. PubMed ID: 15077298
[TBL] [Abstract][Full Text] [Related]
7. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis.
Bendele AM; Chlipala ES; Scherrer J; Frazier J; Sennello G; Rich WJ; Edwards CK
Arthritis Rheum; 2000 Dec; 43(12):2648-59. PubMed ID: 11145022
[TBL] [Abstract][Full Text] [Related]
8. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis.
Nissinen R; Leirisalo-Repo M; Peltomaa R; Palosuo T; Vaarala O
Ann Rheum Dis; 2004 Jun; 63(6):681-7. PubMed ID: 15140775
[TBL] [Abstract][Full Text] [Related]
9. Joint inflammation and cytokine inhibition in rheumatoid arthritis.
Christodoulou C; Choy EH
Clin Exp Med; 2006 Mar; 6(1):13-9. PubMed ID: 16550339
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
[TBL] [Abstract][Full Text] [Related]
11. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
12. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells.
Mathsson L; Lampa J; Mullazehi M; Rönnelid J
Arthritis Res Ther; 2006; 8(3):R64. PubMed ID: 16569263
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.
Young DA; Hegen M; Ma HL; Whitters MJ; Albert LM; Lowe L; Senices M; Wu PW; Sibley B; Leathurby Y; Brown TP; Nickerson-Nutter C; Keith JC; Collins M
Arthritis Rheum; 2007 Apr; 56(4):1152-63. PubMed ID: 17393408
[TBL] [Abstract][Full Text] [Related]
14. Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha.
Williams RO
Methods Mol Biol; 2007; 361():265-84. PubMed ID: 17172717
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis.
Schotte H; Schlüter B; Willeke P; Mickholz E; Schorat MA; Domschke W; Gaubitz M
Rheumatology (Oxford); 2004 Aug; 43(8):960-4. PubMed ID: 15026584
[TBL] [Abstract][Full Text] [Related]
16. Aggressive periodontitis and chronic arthritis: blood mononuclear cell gene expression and plasma protein levels of cytokines and cytokine inhibitors.
Sørensen LK; Havemose-Poulsen A; Bendtzen K; Holmstrup P
J Periodontol; 2009 Feb; 80(2):282-9. PubMed ID: 19186969
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
18. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis.
Mullazehi M; Mathsson L; Lampa J; Rönnelid J
Arthritis Rheum; 2006 Jun; 54(6):1759-71. PubMed ID: 16736518
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis.
Andersson AK; Feldmann M; Brennan FM
Scand J Immunol; 2008 Jul; 68(1):103-11. PubMed ID: 18482208
[TBL] [Abstract][Full Text] [Related]
20. Agents against cytokine synthesis or receptors.
Yamagata T; Ichinose M
Eur J Pharmacol; 2006 Mar; 533(1-3):289-301. PubMed ID: 16457805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
